Smaller-Incision new-generation implantable miniature telescope: Three-months follow-up study

Abstract

Purpose To evaluate three months follow-up of SING IMT implant in patients affected by late-stage AMD Design Prospective cohort study Subjects In a total of 80 eyes of 40 patients who underwent the enrollment tests, 11 patients’ eyes affected by late-stage AMD matched the inclusion criteria and underwent SING IMT implant from February to June 2022. Methods Before surgery, each patient underwent the enrollment examination to verify inclusion and exclusion criteria. Main outcome measures BCVA for distance and for near, IOP, ACD and ECD were evaluated at 1 and 3 months follow up. Also quality of life in doing the activities of daily life was evaluated. Results BCVA for distance and for near improved from baseline to 3 months follow up (23.91 ± 9.418 ETDRS letters and 59.09 ± 11.58 ETDRS letters respectively (p < 0.001). An endothelial cell loss was shown (p < 0.001), with a rate of cell density reduction around 8.3% (baseline vs 3 months). Conclusions SING IMT could be a valid surgical device to improve patients’ sight and quality of life which have been deteriorated by late-stage macular degeneration. Further studies with more patients and longer follow up are needed to confirm our results.